{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T20:02:29Z","timestamp":1792180949091,"version":"4.4.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,3,9]],"date-time":"2019-03-09T00:00:00Z","timestamp":1552089600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,3,9]],"date-time":"2019-03-09T00:00:00Z","timestamp":1552089600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008087","name":"Guthy-Jackson Charitable Foundation","doi-asserted-by":"publisher","award":["no number"],"award-info":[{"award-number":["no number"]}],"id":[{"id":"10.13039\/100008087","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["EY13574"],"award-info":[{"award-number":["EY13574"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000070","name":"National Institute of Biomedical Imaging and Bioengineering","doi-asserted-by":"publisher","award":["EB00415"],"award-info":[{"award-number":["EB00415"]}],"id":[{"id":"10.13039\/100000070","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["DK35124"],"award-info":[{"award-number":["DK35124"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["DK72517"],"award-info":[{"award-number":["DK72517"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neuroinflammation"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Neuromyelitis optica spectrum disorder (herein called NMO) is an inflammatory demyelinating disease that can be initiated by binding of immunoglobulin G autoantibodies (AQP4-IgG) to aquaporin-4 on astrocytes, causing complement-dependent cytotoxicity (CDC) and downstream inflammation. The increased NMO pathology in rodents deficient in complement regulator protein CD59 following passive transfer of AQP4-IgG has suggested the potential therapeutic utility of increasing the expression of complement regulator proteins.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A cell-based ELISA was developed to screen for pharmacological upregulators of endogenous CD55 and CD59 in a human astrocyte cell line. A statin identified from the screen was characterized in cell culture models and rodents for its action on complement regulator protein expression and its efficacy in models of seropositive NMO.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Screening of ~\u200911,500 approved and investigational drugs and nutraceuticals identified transcriptional upregulators of CD55 but not of CD59. Several statins, including atorvastatin, simvastatin, lovastatin, and fluvastatin, increased CD55 protein expression in astrocytes, including primary cultures, by three- to four-fold at 24\u2009h, conferring significant protection against AQP4-IgG-induced CDC. Mechanistic studies revealed that CD55 upregulation involves inhibition of the geranylgeranyl transferase pathway rather than inhibition of cholesterol biosynthesis. Oral atorvastatin at 10\u201320\u2009mg\/kg\/day for 3\u2009days strongly increased CD55 immunofluorescence in mouse brain and spinal cord and reduced NMO pathology following intracerebral AQP4-IgG injection.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Atorvastatin or other statins may thus have therapeutic benefit in AQP4-IgG seropositive NMO by increasing CD55 expression, in addition to their previously described anti-inflammatory and immunomodulatory actions.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12974-019-1448-x","type":"journal-article","created":{"date-parts":[[2019,3,9]],"date-time":"2019-03-09T07:02:36Z","timestamp":1552114956000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["CD55 upregulation in astrocytes by statins as potential therapy for AQP4-IgG seropositive neuromyelitis optica"],"prefix":"10.1186","volume":"16","author":[{"given":"Lukmanee","family":"Tradtrantip","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianjiao","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Yeaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan S.","family":"Verkman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,9]]},"reference":[{"issue":"4","key":"1448_CR1","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1084\/jem.20050304","volume":"202","author":"VA Lennon","year":"2005","unstructured":"Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. 2005;202(4):473\u20137.","journal-title":"J Exp Med"},{"issue":"Pt 5","key":"1448_CR2","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1093\/brain\/awm047","volume":"130","author":"T Misu","year":"2007","unstructured":"Misu T, et al. Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis. Brain. 2007;130(Pt 5):1224\u201334.","journal-title":"Brain."},{"issue":"7","key":"1448_CR3","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/nrneurol.2010.72","volume":"6","author":"S Jarius","year":"2010","unstructured":"Jarius S, Wildemann B. AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance. Nat Rev Neurol. 2010;6(7):383\u201392.","journal-title":"Nat Rev Neurol"},{"issue":"6","key":"1448_CR4","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/S1474-4422(12)70133-3","volume":"11","author":"MC Papadopoulos","year":"2012","unstructured":"Papadopoulos MC, Verkman AS. Aquaporin 4 and neuromyelitis optica. Lancet Neurol. 2012;11(6):535\u201344.","journal-title":"Lancet Neurol"},{"key":"1448_CR5","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/B978-0-12-802395-2.00019-5","volume":"145","author":"R Hoftberger","year":"2017","unstructured":"Hoftberger R, Lassmann H. Inflammatory demyelinating diseases of the central nervous system. Handb Clin Neurol. 2017;145:263\u201383.","journal-title":"Handb Clin Neurol"},{"issue":"7","key":"1448_CR6","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1177\/1352458511432896","volume":"18","author":"BM Greenberg","year":"2012","unstructured":"Greenberg BM, et al. Rituximab dosing and monitoring strategies in neuromyelitis optica patients: creating strategies for therapeutic success. Mult Scler. 2012;18(7):1022\u20136.","journal-title":"Mult Scler"},{"issue":"9","key":"1448_CR7","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/nrneurol.2014.141","volume":"10","author":"MC Papadopoulos","year":"2014","unstructured":"Papadopoulos MC, Bennett JL, Verkman AS. Treatment of neuromyelitis optica: state-of-the-art and emerging therapies. Nat Rev Neurol. 2014;10(9):493\u2013506.","journal-title":"Nat Rev Neurol"},{"issue":"3","key":"1448_CR8","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1586\/14737175.2016.1150178","volume":"16","author":"J Kitley","year":"2016","unstructured":"Kitley J, Palace J. Therapeutic options in neuromyelitis optica spectrum disorders. Expert Rev Neurother. 2016;16(3):319\u201329.","journal-title":"Expert Rev Neurother"},{"issue":"3","key":"1448_CR9","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.autrev.2018.01.001","volume":"17","author":"A Bruscolini","year":"2018","unstructured":"Bruscolini A, et al. Diagnosis and management of neuromyelitis optica spectrum disorder. Autoimmun Rev. 2018;17(3):195\u2013200.","journal-title":"Autoimmun Rev"},{"issue":"Pt 7","key":"1448_CR10","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1093\/brain\/awf151","volume":"125","author":"CF Lucchinetti","year":"2002","unstructured":"Lucchinetti CF, et al. A role for humoral mechanisms in the pathogenesis of Devic\u2019s neuromyelitis optica. Brain. 2002;125(Pt 7):1450\u201361.","journal-title":"Brain."},{"issue":"5","key":"1448_CR11","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1177\/1352458506070145","volume":"13","author":"GJ Hengstman","year":"2007","unstructured":"Hengstman GJ, Wesseling P, Frenken CW, Jongen PJ. Neuromyelitis optica with clinical and histopathological involvement of the brain. Mult Scler. 2007;13(5):679\u201382.","journal-title":"Mult Scler"},{"issue":"Pt 5","key":"1448_CR12","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1093\/brain\/awl371","volume":"130","author":"SF Roemer","year":"2007","unstructured":"Roemer SF, et al. Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain. 2007;130(Pt 5):1194\u2013205.","journal-title":"Brain."},{"key":"1448_CR13","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1093\/brain\/awp309","volume":"133","author":"S Saadoun","year":"2010","unstructured":"Saadoun S, Waters P, Bell BA, Vincent A, Verkman AS, Papadopoulos MC. Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain. 2010;133:349\u201361.","journal-title":"Brain."},{"key":"1448_CR14","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1742-2094-11-16","volume":"11","author":"N Asavapanumas","year":"2014","unstructured":"Asavapanumas N, Ratelade J, Papadopoulos MS, Bennett JL, Levin MH, Verkman AS. Experimental mouse model of optic neuritis with inflammatory demyelination produced by passive transfer of neuromyelitis optica-immoglobulin G. J Neuroinflamm. 2014;11:16.","journal-title":"J Neuroinflamm."},{"key":"1448_CR15","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jaut.2014.02.011","volume":"53","author":"H Zhang","year":"2014","unstructured":"Zhang H, Verkman AS. Longitudinally extensive NMO spinal cord pathology produced by passive transfer of NMO-IgG in mice lacking complement inhibitor CD59. J Autoimmun. 2014;53:67\u201377.","journal-title":"J Autoimmun"},{"issue":"6","key":"1448_CR16","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/S1474-4422(13)70076-0","volume":"12","author":"SJ Pittock","year":"2013","unstructured":"Pittock SJ, et al. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol. 2013;12(6):554\u201362.","journal-title":"Lancet Neurol"},{"issue":"1","key":"1448_CR17","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40478-017-0417-9","volume":"5","author":"X Yao","year":"2017","unstructured":"Yao X, Verkman AS. Marked central nervous system pathology in CD59 knockout rats following passive transfer of neuromyelitis optica immunoglobulin G. Acta Neuropath Commun. 2017;5(1):15.","journal-title":"Acta Neuropath Commun"},{"issue":"1","key":"1448_CR18","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s40478-017-0462-4","volume":"5","author":"X Yao","year":"2017","unstructured":"Yao X, Verkman AS. Complement regulator CD59 prevents peripheral organ injury in rats made seropositive for neuromyelitis optica immunoglobulin G. Acta Neuropath Commun. 2017;5(1):57.","journal-title":"Acta Neuropath Commun."},{"issue":"5\u20136","key":"1448_CR19","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1159\/000463207","volume":"8","author":"SE Svehag","year":"1991","unstructured":"Svehag SE. Adverse effect of clinical intervention on the complement system. Complement Inflam. 1991;8(5\u20136):359\u201369.","journal-title":"Complement Inflam"},{"issue":"2\u20133","key":"1448_CR20","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s12026-013-8422-y","volume":"56","author":"E Ballanti","year":"2013","unstructured":"Ballanti E, Perricone C, Greco E, Ballanti M, Muzio GD, Chimenti MS. Complement and autoimmunity. Immunol Res. 2013;56(2\u20133):477\u201391.","journal-title":"Immunol Res"},{"key":"1448_CR21","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.bbi.2017.04.023","volume":"65","author":"Z Wang","year":"2017","unstructured":"Wang Z, et al. Low expression of complement inhibitory protein CD59 contributes to humerol autoimmunity against astrocyte. Brain Behav Immun. 2017;65:173\u201382.","journal-title":"Brain Behav Immun"},{"issue":"5","key":"1448_CR22","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1002\/ana.21802","volume":"66","author":"JL Bennett","year":"2009","unstructured":"Bennett JL, et al. Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. Ann Neurol. 2009;66(5):617\u201329.","journal-title":"Ann Neurol"},{"issue":"18","key":"1448_CR23","doi-asserted-by":"publisher","first-page":"16516","DOI":"10.1074\/jbc.M111.227298","volume":"286","author":"JM Crane","year":"2011","unstructured":"Crane JM, Lam C, Rossi A, Gupta T, Bennett JL, Verkman AS. Binding affinity and specificity of neuromyelitis optica autoantibodies to aquaporin-4 M1\/M23 isoforms and orthogonal arrays. J Biol Chem. 2011;286(18):16516\u201324.","journal-title":"J Biol Chem"},{"key":"1448_CR24","first-page":"556","volume":"25","author":"L Li","year":"2011","unstructured":"Li L, Zhang H, Varrin-Doyer M, Zamvil SS, Verkman AS. Proinflammatory role of aquaporin-4 in autoimmune neuroinflammation. FASEB J. 2011;25:556\u20131566.","journal-title":"FASEB J"},{"issue":"6","key":"1448_CR25","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1007\/s00401-013-1128-3","volume":"125","author":"PW Phuan","year":"2013","unstructured":"Phuan PW, et al. C1q-targeted monoclonal antibody prevents complement-dependent cytotoxicity and neuropathology in in vitro and mouse models of neuromyelitis optica. Acta Neuropathol. 2013;125(6):829\u201340.","journal-title":"Acta Neuropathol"},{"issue":"1","key":"1448_CR26","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s40478-016-0309-4","volume":"4","author":"X Yao","year":"2016","unstructured":"Yao X, Su T, Verkman AS. Clobetasol promotes remyelination in a mouse model of neuromyelitis optica. Acta Neuropath Commun. 2016;4(1):42.","journal-title":"Acta Neuropath Commun."},{"issue":"11","key":"1448_CR27","doi-asserted-by":"publisher","first-page":"e27412","DOI":"10.1371\/journal.pone.0027412","volume":"6","author":"J Ratelade","year":"2011","unstructured":"Ratelade J, Bennett JL, Verkman AS. Intravenous neuromyelitis optica autoantibody in mice targets aquaporin-4 in peripheral organs and area postrema. PLoS One. 2011;6(11):e27412.","journal-title":"PLoS One"},{"issue":"11","key":"1448_CR28","doi-asserted-by":"publisher","first-page":"6075","DOI":"10.4049\/jimmunol.164.11.6075","volume":"164","author":"S Junnikkala","year":"2000","unstructured":"Junnikkala S, Jokiranta TS, Friese MA, Jarva H, Zipfel PF, Meri S. Exceptional resistance of human H2 glioblastoma cells to complement-mediated killing by expression and utilization of factor H and factor H-like protein 1. J Immunol. 2000;164(11):6075\u201381.","journal-title":"J Immunol"},{"issue":"2","key":"1448_CR29","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1023\/A:1018975928974","volume":"11","author":"A Saheki","year":"1994","unstructured":"Saheki A, Terasaki T, Tamai I, Tsuji A. In vivo and in vitro blood-brain barrier transport of 3-hydroxy-3-methylglutaryl coenzyme a (HMG-CoA) reductase inhibitors. Pharm Res. 1994;11(2):305\u201311.","journal-title":"Pharm Res"},{"issue":"1","key":"1448_CR30","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.pneurobio.2009.02.002","volume":"88","author":"JVD Most","year":"2009","unstructured":"Most JVD, Dolga AM, Nijholt IM, Luiten PGM, Eisel ULM. Statin: mechanism of neuroprotection. Prog Neurobiol. 2009;88(1):64\u201375.","journal-title":"Prog Neurobiol"},{"issue":"5","key":"1448_CR31","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/nri1839","volume":"6","author":"J Greenwood","year":"2006","unstructured":"Greenwood J, Steinman L, Zamvil SS. Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat Rev Immunol. 2006;6(5):358\u201370.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"1448_CR32","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/imm.12902","volume":"154","author":"R Zeiser","year":"2018","unstructured":"Zeiser R. Immune modulatory effects of statins. Immunology. 2018;154(1):69\u201375.","journal-title":"Immunology"},{"issue":"6911","key":"1448_CR33","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/nature01158","volume":"420","author":"S Youssef","year":"2002","unstructured":"Youssef S, et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature. 2002;420(6911):78\u201384.","journal-title":"Nature."},{"issue":"1","key":"1448_CR34","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1111\/j.1471-4159.2006.04354.x","volume":"101","author":"R Pannu","year":"2007","unstructured":"Pannu R, Christie DK, Barbosa E, Singh I, Singh AK. Post-trauma Lipitor treatment prevents endothelial dysfunction, facilitates neuroprotection, and promotes locomotor recovery following spincal cord injury. J Neurochem. 2007;101(1):182\u2013200.","journal-title":"J Neurochem"},{"issue":"1","key":"1448_CR35","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s12974-017-0934-2","volume":"4","author":"X Xu","year":"2017","unstructured":"Xu X, et al. Anti-inflammatory and immunomodulatory mechanisms of atorvastatin in a murine model of traumatic brain injury. J Neuroinflamm. 2017;4(1):167.","journal-title":"J Neuroinflamm"},{"key":"1448_CR36","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s00401-013-1172-z","volume":"126","author":"J Ratelade","year":"2013","unstructured":"Ratelade J, Asavapanumas N, Ritchie AM, Wemlinger S, Bennett JL, Verkman AS. Involvement of antibody-dependent cell-mediated cytotoxicity in inflammatory demyelination in a mouse model of neuromyelitis optica. Acta Neuropathol. 2013;126:699\u2013709.","journal-title":"Acta Neuropathol"},{"key":"1448_CR37","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jtbi.2017.08.020","volume":"433","author":"S Laranjeira","year":"2017","unstructured":"Laranjeira S, Symmonds M, Palace J, Payne SJ, Oriowski P. A mathematical model of cellular swelling in neuromyelitis optica. J Theor Biol. 2017;433:39\u201348.","journal-title":"J Theor Biol"},{"issue":"9","key":"1448_CR38","doi-asserted-by":"publisher","first-page":"e106824","DOI":"10.1371\/journal.pone.0106824","volume":"9","author":"L Tradtrantip","year":"2014","unstructured":"Tradtrantip L, Asavapanumas N, Phuan PW, Verkman AS. Potential therapeutic benefit of C1-estrease inhibitor in neuromyelitis optica evaluated in vitro and in an experimental rat model. PLoS One. 2014;9(9):e106824.","journal-title":"PLoS One"},{"issue":"1","key":"1448_CR39","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1002\/1529-0131(200101)44:1<138::AID-ANR18>3.0.CO;2-G","volume":"44","author":"JC Mason","year":"2001","unstructured":"Mason JC, Lidington EA, Yarwood H, Lublin DM, Haskard DO. Induction of endothelial cell decay-accelerating factor by vascular endothelial growth factor. Arthritis Rheumatol. 2001;44(1):138\u201350.","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"1448_CR40","doi-asserted-by":"publisher","first-page":"C578","DOI":"10.1152\/ajpcell.00339.2001","volume":"282","author":"JC Mason","year":"2002","unstructured":"Mason JC, Lidington EA, Ahmad SR, Haskard DO. bFGF and VEGF synergistically enhance endothelial cytoprotection via decay-accelerating factor induction. Am J Physiol Cell Physiol. 2002;282(3):C578\u201387.","journal-title":"Am J Physiol Cell Physiol"},{"issue":"8","key":"1448_CR41","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1161\/01.RES.0000038151.57577.19","volume":"91","author":"JC Mason","year":"2002","unstructured":"Mason JC, et al. Statin-induced expression of decay-accelerating factor protects vascular endothelium against complement-mediated injury. Circ Res. 2002;91(8):696\u2013703.","journal-title":"Circ Res"},{"issue":"2","key":"1448_CR42","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1046\/j.1365-2567.2003.01733.x","volume":"110","author":"SR Ahmad","year":"2003","unstructured":"Ahmad SR, et al. Decay-accelerating factor induction by tumour necrosis factor-\u03b1, through a phosphatidylinositol-3 kinase and protein kinase C-dependent pathway, protects murine vascular endothelial cells against complement deposition. Immunology. 2003;110(2):258\u201368.","journal-title":"Immunology."},{"issue":"4","key":"1448_CR43","doi-asserted-by":"publisher","first-page":"R130","DOI":"10.1186\/ar2019","volume":"8","author":"AR Kinderlerer","year":"2006","unstructured":"Kinderlerer AR, et al. Statin-induced expression of CD59 on vascular endothelium in hypoxia: a potential mechanism for the anti-inflammatory actions of statins in rheumatoid arthritis. Arthritis Res & Ther. 2006;8(4):R130.","journal-title":"Arthritis Res & Ther"},{"issue":"5","key":"1448_CR44","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.tcm.2006.03.003","volume":"16","author":"JA Beckman","year":"2006","unstructured":"Beckman JA, Creager MA. The nonlipid effects of statins on endothelial function. Trends Cardiovasc Med. 2006;16(5):156\u201362.","journal-title":"Trends Cardiovasc Med"},{"issue":"2","key":"1448_CR45","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.it.2006.12.003","volume":"28","author":"J Greenwood","year":"2007","unstructured":"Greenwood J, Mason JC. Statins and the vascular endothelial inflammatory response. Trends Immunol. 2007;28(2):88\u201398.","journal-title":"Trends Immunol"},{"issue":"11 Suppl 1","key":"1448_CR46","doi-asserted-by":"publisher","first-page":"2708","DOI":"10.1161\/01.STR.0000143319.73503.38","volume":"35","author":"M Endres","year":"2004","unstructured":"Endres M, Laufs U. Effects of statins on endothelium and signaling mechanism. Stroke. 2004;35(11 Suppl 1):2708\u201311.","journal-title":"Stroke."},{"issue":"5","key":"1448_CR47","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1172\/JCI30868","volume":"117","author":"AK Sjogren","year":"2007","unstructured":"Sjogren AK, et al. GGTase-I deficiency reduces tumor formation and improves survival in mice with K-RAS-induced lung cancer. J Clin Invest. 2007;117(5):294\u20131304.","journal-title":"J Clin Invest"},{"issue":"1","key":"1448_CR48","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1124\/jpet.109.160192","volume":"333","author":"KM Sane","year":"2010","unstructured":"Sane KM, et al. A novel geranylgeranyl transferase inhibitor in combination with lovastatin inhibits proliferation and induces autoghagy in STS-26T MPNST cells. J Pharmacol Exp Ther. 2010;333(1):23\u201333.","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"1448_CR49","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1007\/s12031-012-9905-3","volume":"49","author":"X Zhou","year":"2013","unstructured":"Zhou X, et al. Geranylgeranyltransferase I promotes human glioma cell growth through Rac1 membrane association and activation. J Mol Neurosci. 2013;49(1):130\u20139.","journal-title":"J Mol Neurosci"},{"issue":"1","key":"1448_CR50","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1097\/00006123-199807000-00081","volume":"43","author":"M Bredel","year":"1998","unstructured":"Bredel M, Pollack IF, Freund JM, Hamilton AD, Sebti SM. Inhibition of Ras and related G-proteins as a therapeutic strategy for blocking malignant glioma growth. Neurosurg. 1998;43(1):124\u201331.","journal-title":"Neurosurg."},{"issue":"5","key":"1448_CR51","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1158\/1535-7163.MCT-08-1122","volume":"8","author":"J Lu","year":"2009","unstructured":"Lu J, Chan L, Fiji HD, Dahl R, Kwon O, Tamanoi F. In vivo antitumor effect of a novel inhibitor of protein geranylgeranyltransferase-I. Mol Cancer Ther. 2009;8(5):1218\u201326.","journal-title":"Mol Cancer Ther"},{"key":"1448_CR52","unstructured":"O\u2019Dwyer PJ, Gallagher M, Nguyen B, Waddell MJ, Chiorean EG. Phase I accelerated dose-escalating safety and pharmacokinetic (PK) study of GGTI-2418, a novel geranylgeranyltransferase I inhibitor in patients with refractory solid tumors. Ann Oncol. 2010;21:ii42."},{"issue":"3","key":"1448_CR53","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1124\/jpet.113.208595","volume":"347","author":"E van de Steeg","year":"2013","unstructured":"van de Steeg E, et al. Combined analysis of pharmacokinetic and efficacy data of preclinical studies with statins markedly improves translation of drug efficacy to human trials. J Pharmacol Exp Ther. 2013;347(3):635\u201344.","journal-title":"J Pharmacol Exp Ther"},{"key":"1448_CR54","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.expneurol.2010.08.030","volume":"226","author":"TC Piermartiri","year":"2010","unstructured":"Piermartiri TC, et al. Atorvastain prevents hippocampus cell death, neuroinflammation and oxidative stress following amyloid-\u03b2(1-40) administration in mice: evidence for dissociation between cognitive deficits and neuronal damage. Exper Neurol. 2010;226:274\u201384.","journal-title":"Exper Neurol"},{"key":"1448_CR55","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.brainres.2010.11.067","volume":"1371","author":"T Kurata","year":"2011","unstructured":"Kurata T, et al. Atorvastatin and pitavastatin improve cognitive function and reduce senile plague and phosphorylated tau in aged APP mice. Brain Res. 2011;1371:161\u201370.","journal-title":"Brain Res"},{"key":"1448_CR56","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1177\/1352458515571446","volume":"21","author":"S Saadoun","year":"2015","unstructured":"Saadoun S, Papadopoulos MC. Role of membrane complement regulators in neuromyelitis optica. Mult Scler. 2015;21:644\u20131654.","journal-title":"Mult Scler"},{"issue":"50","key":"1448_CR57","doi-asserted-by":"publisher","first-page":"13609","DOI":"10.1523\/JNEUROSCI.2765-08.2008","volume":"28","author":"S Klopfleisch","year":"2008","unstructured":"Klopfleisch S, et al. Negative impact of statins on oligodendrocytes and myelin formation in vitro and in vivo. J Neurosci. 2008;28(50):13609\u201314.","journal-title":"J Neurosci"},{"issue":"5","key":"1448_CR58","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.2353\/ajpath.2009.080947","volume":"174","author":"VE Miron","year":"2009","unstructured":"Miron VE, et al. Statin therapy inhibits remyelination in the central nervous system. Am J Pathol. 2009;174(5):1880\u201390.","journal-title":"Am J Pathol"},{"key":"1448_CR59","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s40263-015-0239-x","volume":"29","author":"G Pihl-Jensen","year":"2015","unstructured":"Pihl-Jensen G, Tsakiri A, Frederiksen JL. Statin treatment in multiple sclerosis: a systematic review and meta-analysis. CNS Drug. 2015;29:277\u201391.","journal-title":"CNS Drug"}],"container-title":["Journal of Neuroinflammation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-019-1448-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12974-019-1448-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-019-1448-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T05:17:36Z","timestamp":1650431856000},"score":1,"resource":{"primary":{"URL":"https:\/\/jneuroinflammation.biomedcentral.com\/articles\/10.1186\/s12974-019-1448-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,9]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1448"],"URL":"https:\/\/doi.org\/10.1186\/s12974-019-1448-x","relation":{},"ISSN":["1742-2094"],"issn-type":[{"value":"1742-2094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,9]]},"assertion":[{"value":"4 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Procedures were approved by the UCSF Institutional Animal Care Use Committee (IACUC). Consent to participate is not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"57"}}